Salivary Gland Malignancies: The Role for Chemotherapy and Molecular Targeted Agents

Seminars in Oncology

Volumn 35, Issue 3, 2008, Pages 309-319

  Surakanti, Sujani G ^a   Agulnik, Mark ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AXITINIB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; MITOXANTRONE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; TRASTUZUMAB; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; SALIVARY GLAND CANCER; SALIVARY GLAND CARCINOMA; SALIVARY GLAND TUMOR; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SALIVARY GLAND NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 44649169606     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.03.009     Document Type: Article

References (82)

1. Speight P.M., and Barrett A.W. Salivary gland tumours. Oral Dis 8 (2002) 229-240
2. Mendenhall W.M., Riggs C.E.J., and Cassisi N.J. Cancer of the head and neck. In: DeVita V.T.J., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology (2005), Lippincott Williams & Wilkins, Philadelphia 662-732
3. Wahlberg P., Anderson H., Biorklund A., Moller T., and Perfekt R. Carcinoma of the parotid and submandibular glands-a study of survival in 2465 patients. Oral Oncol 38 (2002) 706-713
4. Gooden E., Witterick I.J., Hacker D., Rosen I.B., and Freeman J.L. Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital's quality assurance review. J Otolaryngol 31 (2002) 351-354
5. Theriault C., and Fitzpatrick P.J. Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9 (1986) 510-516
6. Sun E.C., Curtis R., Melbye M., and Goedert J.J. Salivary gland cancer in the United States. Cancer Epidemiol Biomarkers Prev 8 (1999) 1095-1100
7. Brandwein M.S., Ferlito A., Bradley P.J., Hille J.J., and Rinaldo A. Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 122 (2002) 758-764
8. Seifert G., and Donath K. Hybrid tumours of salivary glands. Definition and classification of five rare cases. Eur J Cancer B Oral Oncol 32B (1996) 251-259
9. Guzzo M., Andreola S., Sirizzotti G., and Cantu G. Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 9 (2002) 688-695
10. Goode R.K., Auclair P.L., and Ellis G.L. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82 (1998) 1217-1224
11. Spiro R.H., Huvos A.G., and Strong E.W. Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients. Am J Surg 144 (1982) 423-431
12. Kokemueller H., Eckardt A., Brachvogel P., and Hausamen J.E. Adenoid cystic carcinoma of the head and neck-a 20 years experience. Int J Oral Maxillofac Surg 33 (2004) 25-31
13. Batsakis J.G., Regezi J.A., Luna M.A., and el-Naggar A. Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol 103 (1989) 939-944
14. Conley J., and Arena S. Parotid gland as a focus of metastasis. Arch Surg 87 (1963) 757-764
15. Nichols R.D., Pinnock L.A., and Szymanowski R.T. Metastases to parotid nodes. Laryngoscope 90 (1980) 1324-1328
16. Greene F. AJCC Cancer Staging Manual (2002), Springer, New York
17. Spiro R.H. Factors affecting survival in salivary gland cancers. In: McGurk M., and Renehan A.G. (Eds). Controversies in the management of salivary gland disease (2001), Oxford University Press, Oxford 143-150
18. Shah G.V. MR imaging of salivary glands. Magn Reson Imaging Clin N Am 10 (2002) 631-662
19. Vander Poorten V.L., Balm A.J., Hilgers F.J., Tan I.B., Loftus-Coll B.M., Keus R.B., et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85 (1999) 2255-2264
20. Armstrong J.G., Harrison L.B., Spiro R.H., Fass D.E., Strong E.W., and Fuks Z.Y. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116 (1990) 290-293
21. Chen A.M., Garcia J., Lee N.Y., Bucci M.K., and Eisele D.W. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation?. Int J Radiat Oncol Biol Phys 67 (2007) 988-994
22. Katori H., and Tsukuda M. Concurrent chemoradiotherapy with cyclophosphamide, pirarubicin, and cisplatin for patients with locally advanced salivary gland carcinoma. Acta Otolaryngol 126 (2006) 1309-1314
23. Langston M., Farray D., Ruzich J.C., Emami B., Petruzzelli G., and Clark J.I. Pilot study of paclitaxel and carboplatin (P/C) with concurrent radiation therapy (RT) in high risk salivary gland carcinomas (SGC) [abstract]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 24 Suppl 18 (2006) 15538
24. Maruya S., Namba A., Matsubara A., Kakehata S., Takeda I., Shirasaki T., et al. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel. Int J Clin Oncol 11 (2006) 403-406
25. Laurie S.A., and Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24 (2006) 2673-2678
26. Licitra L., Marchini S., Spinazze S., Rossi A., Rocca A., Grandi C., et al. Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 68 (1991) 1874-1877
27. Airoldi M., Brando V., Giordano C., Gabriele P., Bussi M., and Cortesina G. Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Otorhinolaryngol Relat Spec 56 (1994) 105-111
28. Gilbert J., Li Y., Pinto H.A., Jennings T., Kies M.S., Silverman P., et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 28 (2006) 197-204
29. Dimery I.W., Legha S.S., Shirinian M., and Hong W.K. Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 8 (1990) 1056-1062
30. Dreyfuss A.I., Clark J.R., Fallon B.G., Posner M.R., Norris Jr. C.M., and Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60 (1987) 2869-2872
31. Alberts D.S., Manning M.R., Coulthard S.W., Koopmann Jr. C.F., and Herman T.S. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 47 (1981) 645-648
32. Hill M.E., Constenla D.O., A'Hern R.P., Henk J.M., Rhys-Evans P., Breach N., et al. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33 (1997) 275-278
33. Venook A.P., Tseng Jr. A., Meyers F.J., Silverberg I., Boles R., Fu K.K., et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 5 (1987) 951-955
34. Airoldi M., Pedani F., Brando V., Gabriele P., and Giordano C. Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 75 (1989) 252-256
35. de Haan L.D., De Mulder P.H., Vermorken J.B., Schornagel J.H., Vermey A., and Verweij J. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 14 (1992) 273-277
36. Triozzi P.L., Brantley A., Fisher S., Cole T.B., Crocker I., and Huang A.T. 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 59 (1987) 887-890
37. Airoldi M., Pedani F., Succo G., Gabriele A.M., Ragona R., Marchionatti S., et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91 (2001) 541-547
38. Gedlicka C., Schull B., Formanek M., Kornfehl J., Burian M., Knerer B., et al. Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs 13 (2002) 491-495
39. Airoldi M., Fornari G., Pedani F., Marchionatti S., Gabriele P., Succo G., et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20 (2000) 3781-3783
40. Harari P.M., and Huang S.M. Modulation of molecular targets to enhance radiation. Clin Cancer Res 6 (2000) 323-325
41. Agulnik M., Cohen E.W., Cohen R.B., Chen E.X., Hotte S.J., Winquist E., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or ErbB2 expressing adenoid cystic (carcinoma) and non-adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984
42. Chen C.H., Li B.Y., Wan J.T., Sun A., Leu J.S., and Chiang C.P. Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B 25 (2001) 90-96
43. Etges A., Pinto Jr. D.S., Kowalski L.P., Soares F.A., and Araujo V.C. Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 56 (2003) 914-918
44. Fan C.Y., Melhem M.F., Hosal A.S., Grandis J.R., and Barnes E.L. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 127 (2001) 1075-1079
45. Martinez-Barba E., Cortes-Guardiola J.A., Minguela-Puras A., Torroba-Caron A., Mendez-Trujillo S., and Bermejo-Lopez J. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg 25 (1997) 328-334
46. Vered M., Braunstein E., and Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24 (2002) 632-636
47. Yamada K., Iwai K., Okada Y., and Mori M. Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 415 (1989) 523-531
48. Rubin Grandis J., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
49. Barnes L., Rao U., Contis L., Krause J., Schwartz A., and Scalamogna P. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 78 (1994) 74-80
50. Cho K.J., Kim J.Y., Lee S.S., and Oh K.K. Mucoepidermoid carcinoma of the salivary gland--a clinico-pathologic and immunohistochemical study for c-erbB-2 oncoprotein. J Korean Med Sci 12 (1997) 499-504
51. Cho K.J., Lee S.S., and Lee Y.S. Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck 21 (1999) 414-419
52. Dori S., Vered M., David R., and Buchner A. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 31 (2002) 463-467
53. Felix A., El-Naggar A.K., Press M.F., Ordonez N.G., Fonseca I., Tucker S.L., et al. Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 27 (1996) 561-566
54. Glisson B., Colevas A.D., Haddad R., Krane J., El-Naggar A., Kies M., et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10 (2004) 944-946
55. Karja V., Syrjanen S., Kataja V., and Syrjanen K. c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec 56 (1994) 206-212
56. Kernohan N.M., Blessing K., King G., Corbett I.P., and Miller I.D. Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol 163 (1991) 77-80
57. Press M.F., Pike M.C., Hung G., Zhou J.Y., Ma Y., George J., et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54 (1994) 5675-5682
58. Shintani S., Funayama T., Yoshihama Y., Alcalde R.E., Ootsuki K., Terakado N., et al. Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res 15 (1995) 2623-2626
59. Skalova A., Starek, Kucerova V., Szepe P., and Plank L. Salivary duct carcinoma-a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197 (2001) 621-626
60. Skalova A., Starek I., Vanecek T., Kucerova V., Plank L., Szepe P., et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 42 (2003) 348-356
61. Sugano S., Mukai K., Tsuda H., Hirohashi S., Furuya S., Shimosato Y., et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102 (1992) 923-927
62. Giannoni C., el-Naggar A.K., Ordonez N.G., Tu Z.N., Austin J., Luna M.A., et al. c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg 112 (1995) 391-398
63. Nagler R.M., Kerner H., Ben-Eliezer S., Minkov I., and Ben-Itzhak O. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology 64 (2003) 389-398
64. Stenman G., Sandros J., Nordkvist A., Mark J., and Sahlin P. Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer 3 (1991) 128-135
65. Cho K.J., el-Naggar A.K., Ordonez N.G., Luna M.A., Austin J., and Batsakis J.G. Epithelial-myoepithelial carcinoma of salivary glands. A clinicopathologic, DNA flow cytometric, and immunohistochemical study of Ki-67 and HER-2/neu oncogene. Am J Clin Pathol 103 (1995) 432-437
66. Licitra L.F., Locati L.D., Potepan P., Crippa F., Bossi P., Bergamini C., et al. Cetuximab (C225) in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): A monoinstitutional phase II study [abstract]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings 24 Suppl 18 (2006) 5547
67. Hitre E., Boer A., Remenar E., and Takacsi-Nagy Z. Preliminary results of a phase II trial on targeted therapy with cetuximab in EGFR-expressing adenoid cystic carcinoma of the oral cavity. Ann Oncol 17 (2006) 612
68. Glisson B.S., Blumenschein G., Francisco M., Erasmus J., Zinner R., and Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 23 Suppl 16 (2005) 5532
69. Haddad R., Colevas A.D., Krane J.F., Cooper D., Glisson B., Amrein P.C., et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39 (2003) 724-727
70. Agulnik M., Cohen E.E., Cohen R.B., Chen E.X., Hotte S.J., Winquist E., et al. A multicenter phase II study of lapatinib in recurrent or metastatic adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). Ann Oncol 17 Suppl 9 (2006) 179
71. Penner C.R., Folpe A.L., and Budnick S.D. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 15 (2002) 687-691
72. Holst V.A., Marshall C.E., Moskaluk C.A., and Frierson Jr. H.F. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12 (1999) 956-960
73. Jeng Y.M., Lin C.Y., and Hsu H.C. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154 (2000) 107-111
74. Hotte S.J., Winquist E.W., Lamont E., MacKenzie M., Vokes E., Chen E.X., et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23 (2005) 585-590
75. Slevin M.J., Mais K.L., Bruce I., Ward T., Carrington B., Hulse P., et al. Imatinib with cisplatin in recurrent and/or metastatic salivary adenoidcystic carcinoma-response assessed by FDG-PET scanning [abstract]. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22 Suppl 14 (2004) 5604
76. Guigay J.M., Bidault F., Temam S., Janot F., Raymond E., and Faivre S. Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: a phase II study [abstract]. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings 25 Suppl 18 (2007) 6086
77. Lim J.J., Kang S., Lee M.R., Pai H.K., Yoon H.J., Lee J.I., et al. Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 32 (2003) 552-561
78. Doi R., Kuratate I., Okamoto E., Ryoke K., and Ito H. Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas. J Oral Pathol Med 28 (1999) 259-263
79. Rugo H.S., Herbst R.S., Liu G., Park J.W., Kies M.S., Steinfeldt H.M., et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23 (2005) 5474-5483
80. Nasser S.M., Faquin W.C., and Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 119 (2003) 801-806
81. Shadaba A., Gaze M.N., and Grant H.R. The response of adenoid cystic carcinoma to tamoxifen. J Laryngol Otol 111 (1997) 1186-1189
82. Locati L.D., Quattrone P., Bossi P., Marchiano A.V., Cantu G., and Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 14 (2003) 1327-1328